Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02971748
What this trial is testing

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Who this might be right for
Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Breast Inflammatory Carcinoma+2 more
M.D. Anderson Cancer Center 36
Large-scale testing (Phase 3)Study completedNCT00293540
What this trial is testing

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

Who this might be right for
Breast Cancer
International Breast Cancer Research Foundation 249
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Large-scale testing (Phase 3)Study completedNCT00329940
What this trial is testing

Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 200
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Study completedNCT01972984
What this trial is testing

Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients

Who this might be right for
Breast Cancer
Ottawa Hospital Research Institute 20
Large-scale testing (Phase 3)Ended earlyNCT05207709
What this trial is testing

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 61
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Large-scale testing (Phase 3)Study completedNCT00201851
What this trial is testing

Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
International Breast Cancer Research Foundation 740
Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Testing effectiveness (Phase 2)Ended earlyNCT00661531
What this trial is testing

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Who this might be right for
Breast CancerCancer of the BreastNeoplasms, Breast
Georgetown University 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07394946
What this trial is testing

Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

Who this might be right for
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Cancer Care Hospital & Research Centre Foundation, Lahore 126
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)WithdrawnNCT00615524
What this trial is testing

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone-receptor Positive Breast Cancer
GlaxoSmithKline
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Not applicableLooking for participantsNCT07617025
What this trial is testing

Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer

Who this might be right for
Breast Cancer
Angela Toss 100
Next Page